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Summary: Succinyldithiocholine was utilized as a substrate analogue of succinyldicholine to study normal
and atypical serum pseudocholinesterase (EC 3.1.1.8). In the method, the enzyme acts on Succinyldithiocholine
to release thiocholine, which reacts with 5,5'-dithio-bis-(2-nitrobenzoic acid) to produce a coloured compound
with maximal absorbance at 410 nm. The procedure appears to be precise (between-day analysis gives a
coefficient of variation between 1.1 and 3.7%) and amenable to automation, permitting routine use in any
laboratory. The reference interval for 300 healthy adults with "usual" cholinesterase genotype was estimated
to be 34—77 U/l, with a significant difference between males and females (40—78 U/l for men and 33—76 U/l
for women, ρ < 0.01). The median activity in 105 individuals with "heterozygous" cholinesterase genotype
was 22 U/l (range 5-35 U/l), and for 14 "atypical" homozygotes 1.5 U/l (range 1-4 U/l). The assay with
Succinyldithiocholine may offer a direct procedure for preoperative screening of individuals with an abnormal
response to the muscle relaxant succinyldicholine, thus avoiding the determination of genotype by measurement
of inhibitor numbers.
Introduction
The determination of human serum pseudocholines-
terase (acylcholine acylhydrolase, EC 3.1.1.8) cata-
lytic activity is frequently requested for the detection
of patients with atypical forms of the enzyme which
reacts abnormally with succinyldicholine (suxame-
thonium), employed as a neuromuscular blocking
agent (1). This is a qualitative variation of the enzyme
activity which finds its analytical expression in differ-
ences of substrate specificity and susceptibility to in-
hibition (2—4), and its clinical expression in pro-
longed apnoea in the patients during anaesthesia,
resulting from failure of the atypical enzyme to hy-
drolyse suxamethonium (5).
Usually, for biochemical identification of succinyldi-
choline-sensitive individuals, the standard reaction is
run with and without the inhibitors, notably dibucaine
(2) and fluoride (6). But the kinetic behaviour of
*) Presented in part at the 13th International Congress of
Clinical Chemistry, The Hague, The Netherlands, July 1987.
normal and atypical cholinesterases could, in part, be
a function of the substrate and/or inhibitor employed
(7). Furthermore, some patients who would not be
expected to possess a gross abnormality of succinyldi-
choline hydrolysis on the basis of inhibitory criteria
in vitro can be quite clearly shown to be sensitive on
exposure to this agent in vivo (1). A direct assay,
suitable for routine analyses, without the use of in-
hibitors is therefore desirable.
The purpose of the present paper is to describe a
preoperative screening procedure, adaptable to au-
tomatic analysers, for the direct detection of human
sera with atypical succinyldicholine sensitivity. Suc-
cinyldithiocholine is used as the substrate, as proposed
by Hersh et al. (8). This compound is an analogue of
the natural substrate succinyldicholine (9), from
which it differs much less than other substrates fre-
quently used, i.e. acetylthiocholine (10), butyryl-
thiocholine (11), propionylthiocholine (12), benzoyl-
choline (13), and /^-hydroxybenzoylcholine (14). In
particular, the substitution of sulfur for oxygen results
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in no significant change in the kinetic properties of
the enzyme (15). The principle of the method is the
measurement of the rate of production of thiocholine
when succinyldithiocholine is hydrolysed. This is ac-
complished by the procedure of Ellman in which the
thiocholine produced by enzymic hydrolysis is meas-
ured by reaction with 5,5'-dithio-bis-(2-nitrobenzoic
acid) (15). The assay was compared with a benzoyl-
choline system (13) directly derived from the classic
method of Kalow & Genest (2), which is considered
to be the best available for distinguishing between
succinyldicholine-sensitive and nonsensitive patients
(11).
Materials and Methods
Blood samples
Sera containing the homozygous "atypical" (AA) enzyme used
for this study were obtained from hospital patients who expe^
rienced prolonged apnoea (20 min or more) when treated with
succinyldicholine in conjunction with surgery. "Heterozygous"
(UA) enzymes were, pbtained from the preoperative routine
cholinesterase analysis of all surgical cases in our hospital.
Specimens of serum were also obtained from hospitalized pa-
tients with terminal stage hepatic cirrhosis and associated
"usual" (UU) cholinesterase activity, in order to study the
performance of the evaluated method in the detection of quan-
titative defects of the enzyme. Finally, 300 genotypically normal
subjects (UU) served as a control group (150 women and 150
men, age range 20 to 65 years).
Blood was taken from an antecubital vein and allowed to clot;
after centrifugation, the unhaemolysed serum was separated
from the cells and stored at —20 °C until required. Under such
conditions of storage, cholinesterase activity has been shown
to be constant for several years (1,12).
Measurement of enzyme catalytic activity
Pseudocholinesterase catalytic concentration was expressed as
U (μηιοί - min'1). All the enzymatic determinations were carried
out in duplicate on a Cobas Bio analyser (F. Hoffman La
Roche and Co., Ltd., Basle, Switzerland) and the mean value
was calculated. The precision of this analyser is + 0.001 A at
410 nm.
Benzoylcholine as substrate
Pseudocholinesterase assay using benzoylcholine as substrate
was performed according to Panteghini & Bonora (13). In par-
ticular, for dibucaine inhibition, a concentration of 350 μιηοΐ/ΐ
of the inhibitor was used (13).
Succinyldithiocholine as substrate
The "Atypical Cholinesterase" assay was a gift from Sclavo
S. p. A., Siena, Italy (kit product No. 81196). The assay is based
on the method of Hersh et al. (8): the hydrolysis of Succinyl-
dithiocholine is assayed by reacting the liberated thiol with 5,5'-
dithio-bis-(2-nitrobenzoic acid), analogous to the procedure of
Ellman et al. (15). More than 90% of the choline released is
derived from the first step of Succinyldithiocholine hydrolysis;
the next step, conversion of succinylmonothiocholine to succinic
acid, proceeds very slowly (16). The enzymatic activity was
calculated using 1360 m2 · mol"1 as the molar lineic absorbance
value for 5-thio-2-nitrobenzoic acid, the product of the reaction
(13).
Reagents
The kit, not commercially available at the time of writing,
consists of separate reagents for "Chromogen" and "Substrate".
The optimal concentrations for reagent solutions had been
determined in previous titration experiments (Tabacco, data not
published).
·· f
Chromogen
5,5'-Dithio-bis-(2-nitrobenzoic acid) 0.8 mmol/1 in 50 mmol/1
phosphate buffer, pH 7.2, containing 0.6 g of Lialet detergent
per liter. This is stable for at least one year if kept refrigerated
in a dark bottle.
Substrate
Succinyldithiocholine iodide, 5 mmol/1 in solvent (dimethyl
sulphoxide and ethanol, 75 + 25 by vol.). This solution was
diluted 1:10 with Chromogen reagent for use. The working
solution is stable for up to ten days when stored at 4 °C
Procedure
The Cobas Bio was operated according to the setting shown in
table 1, unless otherwise stated.
Tab. 1. Parameter listing for determination of pseudocholin-
esterase catalytic activity on the Cobas Bio by the
proposed method.
Reaction
Units
Calculation factor
Standard concentration
Limit
Temperature
Type of analysis
Wavelength
Sample volume
Diluent volume
Reagent volume
Jncubation time
Start reagent (substrate) volume
Time of first reading
Time interval
Number of readings
Blanking mode
U/l
613
0
0.25
37 °C
3 (reaction rate)
410 nm
30 μΐ
30 μΐ
180 μι
120s
20 μΐ
90s
10s
21
1 (reagent blank)
Results
Determination of Pseudocholinesterase cata-
lytic activity
The spontaneous hydrolysis of Succinyldithiocholine
was minimal (ΔΑ/min < 0.001) with the reagent con-
ditions used in the test.
A calibration curve relating serum volume to the
hydrolysis of Succinyldithiocholine was prepared, us-
ing serum with an activity of 54 U/l. The hydrolysis
rate of Succinyldithiocholine was linearly related to
the volume of serum up to 30 μΐ (fig* 1).
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Fig. 1. Effect of amount of serum used in the assay system on
the measured pseudocholinesterase catalytic activity.
The incubation time of 120 s assures the conclusion
of the nonspecific reaction between the sulphydryl
groups of serum and 5,5'-dithio-bis-(2-nitrobenzoic
acid) before the start of the enzyme activity determi-
nation. Investigation of the effect of the lag time on
the linearity of the enzymatic reaction showed that
the best linearity is obtained with a lag phase of at
least 90 s (tab. 2).
Tab. 2. Effect of lag time on the linearity of the enzymatic
reaction.
Lag time, s No. of linear readings vs
total readings, %
30
45
60
75
90
105
67
70
77
85
95
100
cholinesterase are shown in table 3. The coefficient of
variation in serial analyses is between 0.9 and 2.8%;
between-day analysis of 10 observations for five dif-
ferent serum samples gives coefficients of variation
between 1.1 and 3.7%.
Tab. 3. Precision of pseudocholinesterase determination by the
evaluated method.
Within-run (n =
Mean,
U/l
1.8
17.6
30.3
48.3
87.2
SD,
U/l
0.05
0.26
0.36
0.43
0.87
20)
cv,
2.8
1.5
1.2
0.9
1.0
Between-day (n =
Mean,
U/l
1.9
17.7
30.0
49.0
86.9
SD,
U/l
0.07
0.44
0.42
0.64
0.96
-- 10)
cv,
3.7
2.5
1.4
1.3
1.1
Interference studies
The addition of various kinds of anticoagulant, such
as ethylenediaminetetraacetic acid dipotassium salt
(2.5 mmol/1), sodium citrate (20 mmol/1) or lithium
heparin (1 g/1) had no effect on pseudocholinesterase
activity in the method being evaluated. On the other
hand, sodium fluoride, a known inhibitor of pseu-
docholinesterase (6), at a concentration of 50 mmol/1,
reduces cholinesterase activity by 50%. Reducing sub-
stances, i.e. ascorbic acid, glucose, creatinine, and
uric acid do not interfere at concentrations up to 140
μιηοΐ/ΐ, 55 mmol/1, 4500 μιηοΐ/ΐ, and 2000 μιηοΐ/ΐ,
respectively. Again, albumin up to 150 g/1 does not
interfere with the evaluated.method. Table 4 shows
the interference studies on pseudocholinesterase de-
termination for increasing concentrations of haemo-
globin, triacylglycerols, and bilirubin. Finally, succi-
nyldithiocholine is not hydrolysed by human red-cell
cholinesterase (EC 3.1.1.7).
Linearity
Under the described standard assay conditions, the
reaction is linear up to 90 U/l of serum pseudocho-
linesterase (ΔΑ/min = 0.147). Serum with an activity
of 88 U/l was serially diluted in saline; for this spec-
imen, the theoretical results were 88, 44, 22, 11, 5.5,
3, and 1.5 U/l; the corresponding experimental ab-
sorbance values per min were respectively 0.144,
0.077, 0.042, 0.020, 0.009, 0.005, and 0.002. This
response is highly linear (r == 0.9987; standard error
of estimation, 0.0089).
Precision
Precision studies using human sera with low, normal,
and above-normal catalytic concentrations of pseudo-
Reference interval
After conditions for the method were established, the
procedure was applied to the determination of serum
pseudocholinesterase catalytic activity in apparently
healthy subjects. Employing nonparametric determi-
nation of percentiles (17), we determined the reference
limits of pseudocholinesterase activity in 300 individ-
uals with normal serum biochemical and haematolog-
ical tests (dibucaine number > 75) and without clin-
ical evidence of diseases or conditions that might
depress or increase cholinesterase activity. The refer-
ence interval was estimated to be 34-77 U/l (95%
central range). The reference limits for males (40—78
U/l) were significantly higher than those for females
(33-76 U/l) CP < °-°l), in accordance with other
studies (13, 14, 18, 19).
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Tab. 4. Inferference studies on pseudocholinesterase catalytic
activity determination with the evaluated method.
Original serum
u/i
49
50
32
Observed activity
U/i
50
49
49
27*)
3*)
50
49
44*)
36*)
32
32
31
31
•29*)
25*)
Haemoglobin
8/1
0.25
0.50
1.00
2.00
4.00
Triacylglycerols
mmol/1
4
6
8
16
Bilirubin
μπιοΐ/ΐ
65
90
128
170
265
342
*) Significantly different value from original serum at p < 0.01.
Comparison studies in pathological condi-
tions
238 patients were investigated during the course of
this work:
a) 14 were homozygous for the "atypical" enzyme;
b) 195 were "heterozygous" for the usual and the
atypical gene;
c) 29 had "usual" enzyme and associated severe im-
pairment of hepato-cellular function (hepatic cir-
rhosis in terminal stage).
Results for pseudocholinesterase catalytic activities
and dibucaine numbers for the three groups compared
with the reference group (see above) are shown in
table 5. Comparison between pseudocholinesterase
catalytic activity, obtained with the present method,
and dibucaine number is also presented in figure 2.
The median value of the homozygous AA patients
was 1.5 U/l with a maximum value of 4 U/L The
"heterozygous" UA patients were included within the
range 5—35 U/l. Analysis of this group shows a large
excess of female over male patients mainly in the
subgroup with cholinesterase Values between 5 and
15 U/l (fig. 3). In particular, about 50% of the subjects
of this subgroup were pregnant women. Of the 29
cirrhotic patients, 28 fell within the range 6—15 U/l.
The 29th case, having a value of 4 U/L, was, however,
exceptional (pseudocholinesterase activity with ben-
zoylcholine as substrate was only 185 U/l, namely
about 9% of median reference value).
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Fig. 2. Correlation between serum pseudocholinesterase cata-
v
 lytic activity obtained with the evaluated procedure (y-
axis) and dibucaine number (x-axis).
Solid circle: "usual" enzyme (n = 300);
open square: "heterozygous" enzyme (n == 195);
solid square: "atypical" enzyme (n = 14);
open circle: "usual" enzyme and liver cirrhosis (n = 29).
The dashed line indicates 2.5 SD below the mean activity
for "usual" enzyme.
Tab. 5. Serum pseudocholinesterase catalytic concentration and dibucaine numbers (median values and ranges) in the groups of
studied patients.
Patients
UU genotype
UA genotype
AA genotype
UU genotype +
liver cirrhosis
No.
of cases
300
195
14
29
Pseudocholinesterase
catalytic concentration, U/l
(benzoylcholine)*)
2117(1754-3883)
1340 (445-1920)
625 (370-1480)
503 (185-680)
Dibucaine number,
%*)
80(76-84)
64(50-73)
26(17-35)
82(75-88)
Pseudocholinesterase
catalytic concentration, U/l
(succinyldithiocholine)**)
51 (33-79)
22 (5-35)
1.5 (1- 4)
11 (4^-15)
*) Method in ref. (13)
**) This method.
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Total UA patients
n = 195
5- 15 U/l
n = 36
7 Males
(19.4%)
\
Range of
pseudocholinesterase values
16-35 U/l
n = 159
29 Females
(80.6%)
51 Males
(32.0%)
\
108 Females
(68.0%)
19 Pregnant 10 Non pregnant
Fig. 3. Analysis of the genotype UA patients included in this study.
48 Pregnant 60 Non pregnant
The optimum dividing line between the pseudocholin-
esterase activities of sensitive and nonsensitive indi-
viduals has been recommended by Dietz et al. (12) as
2.5 SD below the mean activity for genotypically
normal subjects. For the present method the corre-
sponding cut-off value is 26 U/l (fig. 2). This finding
compares favorably with that recently reported by
Faye & Evans, who used succinyldicholine as substrate
(20).
Discussion
The proposed method was developed in an attempt
to improve the prediction of succinyldicholine sensi-
tivity by direct measurement of the in vitro rate of
succinyldithiocholine hydrolysis. This assumption is
substantiated by the work of Hersh et al. (8) who
showed that succinyldithiocholine, as an analogue of
succinyldicholine, is a substrate for pseudocholines-
terase. Thus, the ability to hydrolyse succinyldithio-
choline itself should be the criterion in detecting suc-
cinyldicholine-sensitive individuals and should over-
come the problems of extrapolating from studies with
other nonpharmacological substrates with and with*
out inhibitor (4, 7). In agreement with the recommen-
dations of Dietz et al. (12), values of < 26 U/l could
be tentatively regarded as suggesting succinyldicholine
sensitivity. Any individual with a pseudocholinester-
ase catalytic activity below this critical level would be
sensitive to succinyldicholine, regardless of genotype.
The present method results in extremely low activities
with the "atypical" genotype (< 4 U/l), thereby per-
mitting a clear differentiation between the homozy-
gous and other groups of patients studied. Further-
more, unlike the methods with nonpharmacological
substrates, a direct relationship was found between
serum cholinesterase activity and the pathological re-
sponse to succinyldicholine among the homozygous
patients.
Cholinesterase activities of the "heterozygous" UA
subjects indicate that several patients with this geno-
type can be sensitive to succinyldicholine. In partic-
ular, 135 patients (69%) with genotype UA have
cholinesterase activity < 26 U/l. This percentage is
remarkably higher than those found by Dietz et al.
(20%) using propionylthiocholine as substrate (12).
However, Viby Mogensen (21) found that almost 50%
of patients with this genotype experience a moderately
prolonged reaction to succinyldicholine. Therefore,
succinyldithiocholine appears to be a more sensitive
indicator substrate of succinyldicholine sensitivity
than is propionylthiocholine. The clinical implication
of these findings is evident; mainly if the cholinester-
ase activity is reduced for environmental reasons, e. g.,
because of a concomitant pregnancy, a clinically sig-
nificant prolonged paralysis may result in UA sub-
jects. In Whittaker's opinion (1) the UA "heterozy-
gous" pregnant women having 50% or less of the
average normal activity will probably be sensitive to
succinyldicholine. In our study about 50% of the
subjects of the "heterozygous" subgroup with lower
cholinesterase activities (< 15 U/l) were pregnant
women. Thus, a higher proportion of "heterozygous"
women would be expected to show sensitivity to suc-
cinyldicholine during pregnancy than when nonpreg-
nant.
There are acquired causes for low pseudocholinester-
ase catalytic activity (1); in such circumstance the
action of the inhibitors is normal. Nevertheless, pro-
longed apnoea following succinyldicholine has been
reported in these patients in spite of the normal geno-
type (1). Viby Mogensen (22) shows that in these
subjects the duration of succinyldicholine action in-
creases with decreasing serum pseudocholinesterase
activity. Also with the present method, it was possible
to detect low enzyme activities in these subjects per-
mitting a correlation of the level of pseudocholines-
terase catalytic activity with the theoretical duration
of apnoea following the administration of succinyldi-
choline.
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Recently some workers have used succinyldicholine-
based procedures for assaying pseudocholinesterase
(20, 23, 24). However their methods are too cumber-
some for routine use in the clinical laboratory, and
sometimes the autohydrolysis of succinyldicholine
makes difficult the determination of the lower pseu-
docholinesterase activities (23). With our test a large
number of sera can be tested easily; therefore, the
method is well suited for use in the routine clinical
chemistry laboratory. Unlike the assay proposed by
Abernethy et al. (23) which utilizes a single-point
measurement, this system continually monitors the
change in absorbance, thus alleviating the necessity
for precise timing. Even trace amounts of succinyldi-
thiocholine hydrolysis can be detected with high sen-
sitivity. In particular, the use of an automatic analyser
allows the measurement of the enzyme activity at
levels of 1 U/l. Finally, the reagents required are com-
mercially available and the procedure appears to be
applicable to several different types of automatic ana-
lysers.
The most important clinical result of this study is that
when only the screening of a surgical population for
succinyldicholine sensitivity is desired, the proposed
method enables the preoperative identification of pa-
tients who will have an abnormal response to succi-
nyldicholine, without the determinatipn of genotype
by the measurement of inhibitor numbers. Indeed
genotyping specimens, certainly best done by existing
methods (2,12,13), is complementary to the detection
of sensitive individuals by our method. In particular,
if preanaesthesia screening is used, it would be wise
to prohibit the use of suxamethonium if the cholin-
esterase activity is less than 26 U/l, although, in agree-
ment with Dietz et al. (12)^ there will be some patients
with values below 26 U/l who could probably tolerate
succinyldicholine well. Theoretically, our method may
allow a direct estimate of apnoea time^ and this should
be confirmed by clinical trials with the use of a nerve
stimulator.
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